Dr Reddy's buys injectable products portfolio from Eton Pharma
Indian drug major Dr Reddy’s Laboratories (BSE: 500124), along with its subsidiaries, has acquired a portfolio of branded and generic hospital injectable products from Deer Park, Illinois-based Eton Pharmaceuticals (Nasdaq: ETON).
The portfolio includes the Biorphen (phenylephrine hydrocholoride) Injection and Rezipres (ephedrine hydrochloride) Injection new drug applications (NDAs) with nine separate combinations of strengths and presentations and one first-to-file approved Abbreviated NDA for cysteine hydrochloride for the USA. One strength each of Biorphen and Rezipres are currently commercially available in the USA for the treatment of hypotension occurring in the setting of anesthesia. The acquisition will complement Dr Reddy’s US institutional business with limited competition injectable products.
Deal worth $50 million
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze